Evidence map›Paper›PMID 40448172›Full record

ArticleJournal of translational medicine2025

SLIT3-mediated intratumoral crosstalk induces neuroblastoma differentiation via a spontaneous regression-like program.

Meiling Liu, Dekang Lv, Wenjing Yan, Yi Wu, Shulan Wang, Luoxuan Wang, Jie Lei, Deshun Zeng, Zifeng Wang, Fang Liu and 4 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Meiling LiuState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Psychobehavioral Cancer Research Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Dekang LvInstitute of Cancer Stem Cell, Dalian Medical University, 9 West Section, Lvshun South Road, Dalian, 116044, Liaoning, China.
Wenjing YanInstitute of Cancer Stem Cell, Dalian Medical University, 9 West Section, Lvshun South Road, Dalian, 116044, Liaoning, China.
Yi WuState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Psychobehavioral Cancer Research Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Shulan WangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Psychobehavioral Cancer Research Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Luoxuan WangInstitute of Cancer Stem Cell, Dalian Medical University, 9 West Section, Lvshun South Road, Dalian, 116044, Liaoning, China.
Jie LeiState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Psychobehavioral Cancer Research Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Deshun ZengState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Psychobehavioral Cancer Research Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Zifeng WangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Psychobehavioral Cancer Research Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Fang LiuState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Psychobehavioral Cancer Research Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Bing DengState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Psychobehavioral Cancer Research Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Quentin LiuState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Psychobehavioral Cancer Research Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. liuq9@mail.sysu.edu.cn.
Bin HeState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Psychobehavioral Cancer Research Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. hebin@sysucc.org.cn.
Min YanState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Psychobehavioral Cancer Research Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. yanmin@sysucc.org.cn.ORCID 0000-0001-9922-5469

Funding

the National Natural Science Foundation of China 82341020the Science Fund for Creative Research Groups of the National Natural Science Foundation of China 82321003
6 · The paper itself

Abstract

backgroundNeuroblastoma, the most common pediatric extracranial solid tumor, has heterogeneous clinical outcomes ranging from malignant progression to spontaneous regression. With the highest frequency of the elusive spontaneous regression, low-risk INSS Stage 4S neuroblastoma represents an ideal model for mechanistic investigation. Spontaneous regression is often accompanied by tumor differentiation, but the mechanisms underlying this process remain largely unclear.

methodsSingle-nucleus transcriptomics (snRNA-seq) data of neuroblastoma samples were obtained from the Synapse repository to investigate the composition of heterogeneous tumor cell clusters. The feature of the Stage 4S-specific tumor cell subpopulation was revealed through differential expression analysis, pathway enrichment analysis and pseudotime analysis, followed by clinical significance validation on public cohort datasets. The biological function of secreted SLIT3 was validated using multiple in vitro models, including recombinant protein treatment, conditioned medium treatment, and cell lines coculture, to confirm the intratumoral crosstalk effect. Orthotopic and subcutaneous xenograft models were established to verify SLIT3's in vivo function. Cellular bulk RNA-seq analysis was performed with or without SLIT3 recombinant protein treatment to discover the downstream pathways activated by SLIT3, followed by validation with specific pathway inhibitors.

resultsAnalysis of snRNA-seq revealed a distinct subpopulation of tumor cells within INSS Stage 4S neuroblastoma, characterized by a spontaneous regression-like program progressing toward differentiation. Activated SLIT-ROBO signaling was found in the Stage 4S-specific tumor cell subpopulation, which strongly correlated with favorable prognosis. Further investigation into the secreted ligands in SLIT-ROBO related pathways revealed that SLIT3 displayed the most potent enrichment in Stage 4S tumors and the strongest differentiation-inducing effect. In vitro experiments using recombinant SLIT3 protein, conditioned medium, and cell lines coculture consistently demonstrated the capacity of SLIT3 to induce neuroblastoma cell differentiation via intratumoral crosstalk, as evidenced by increased neurite outgrowth and elevated expression of neuronal differentiation markers. Both orthotopic xenograft and subcutaneous xenograft models demonstrated that SLIT3 expression suppressed tumor growth, leading to in vivo tumor differentiation. Mechanistically, PLCβ/PKC signaling mediates the SLIT3-induced neuroblastoma cell differentiation.

conclusionsStage 4S-specific tumor cell subpopulation exhibits a spontaneous regression-like program, from which SLIT3 mediates intratumoral crosstalk and promotes neuroblastoma differentiation via PLCβ/PKC signaling. These findings provide new insights into the mechanism of spontaneous regression in neuroblastoma and offer novel therapeutic targets for differentiation-based treatment strategies.

Indexed as

Cell DifferentiationMembrane ProteinsNeoplasm Regression, SpontaneousNeuroblastomaAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceReproducibility of ResultsSignal TransductionXenograft Model Antitumor AssaysMembrane ProteinsSLIT3 protein, humanDifferentiation induction therapyIntra-tumor cell heterogeneityNeuroblastomaSLIT3SLIT-ROBO signaling

Identifiers

PMID40448172
PMCPMC12123822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.